Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Darmerica, LLC

Has Darmerica, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated December 8, 2025.

Letter facts

Letter date
December 8, 2025 (2025-12-08)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Manufacturer / API
Products named
Active pharmaceutical ingredients (APIs)Drugs
Violation categories
MisbrandingCGMP / insanitary conditionsFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA cited Darmerica for CGMP deviations in API repackaging, including inadequate quality unit oversight, deficient supplier qualification, incomplete complaint and recall investigations, and releasing APIs before testing. Drugs were also misbranded due to labeling and listing failures.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • CGMP deviations for APIs (adulterated drugs, 501(a)(2)(B))
  • Failure of quality unit oversight
  • Inadequate supplier evaluation/qualification
  • Inadequate complaint and recall investigations
  • Inadequate pre-release testing of APIs
  • Misbranding due to false or misleading labeling (502(a))
  • Misbranding due to lack of adequate directions for use (502(f)(1))
  • Misbranding due to failure to list drugs (502(o))

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.